1. Home
  2. YCBD vs ERNA Comparison

YCBD vs ERNA Comparison

Compare YCBD & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo cbdMD Inc.

YCBD

cbdMD Inc.

HOLD

Current Price

$0.69

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

HOLD

Current Price

$5.95

Market Cap

7.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YCBD
ERNA
Founded
2015
2018
Country
United States
United States
Employees
42
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
7.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
YCBD
ERNA
Price
$0.69
$5.95
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
148.8K
52.8K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.29
EPS
N/A
N/A
Revenue
N/A
$582,000.00
Revenue This Year
$12.70
N/A
Revenue Next Year
$7.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.13
52 Week High
$2.56
$15.88

Technical Indicators

Market Signals
Indicator
YCBD
ERNA
Relative Strength Index (RSI) 40.82 40.10
Support Level $0.62 $0.23
Resistance Level $0.84 $15.88
Average True Range (ATR) 0.04 0.81
MACD -0.00 -0.54
Stochastic Oscillator 14.65 4.76

Price Performance

Historical Comparison
YCBD
ERNA

About YCBD cbdMD Inc.

cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: